NYMC Faculty Publications

First Use of Upfront Polatuzumab Vedotin in Post-transplant Lymphoproliferative Disorder: A Case Report

Author Type(s)

Faculty

DOI

10.7759/cureus.56409

Journal Title

Cureus

First Page

56409

Last Page

56409

Document Type

Case Report

Publication Date

3-18-2024

Department

Medicine

Keywords

large b-cell lymphoma; lymphoproliferative malignancy; polatuzumab vedotin; post-transplant lymphoproliferative disorders; r-chop therapy

Disciplines

Medicine and Health Sciences

Abstract

Post-transplant lymphoproliferative disorder (PTLD) is a condition that is highly variable in presentation but life-threatening for post-transplant, immunosuppressed patients. Current standard management in PTLD sees the use of a chemoimmunotherapy regimen similar to the management of diffuse large B-cell lymphoma. Here, we discuss the case of a 33-year-old male with a history of renal transplant, hemodynamically stable, who presented with fevers and night sweats lasting one month. Investigations revealed multiple masses in his liver, the largest of which was biopsied and revealed diffuse large B-cell lymphoma. PTLD is an important malignancy in patients who have received immunosuppression, but the treatment is heterogeneous, based on subtype and patient status. This case, where the addition of polatuzumab to the standard rituximab, cyclophosphamide, doxorubicin, and vincristine (R-CHOP) regimen led to favorable results, demonstrates the potential for a new standard treatment regimen for this disease.

Link to Full Text

Share

COinS